Search

A recent study conducted at Tabriz University of Medical Sciences in Iran explored the immunomodulatory effects of Bicalutamide in prostate cancer by regulating dendritic cell maturation. The research focused on the potential of Bicalutamide, a nonsteroidal anti-androgen, to modulate immune responses mediated by dendritic cells. Results indicated that Bicalutamide treatment induced an immunogenic and matured phenotype in dendritic cells, suggesting potential anti-tumor effects through the modulation of immune responses. This study holds promise for the development of novel therapies, including combination therapies, in the treatment of prostate cancer. [Extracted from the article]

The article discusses a Phase 3 clinical trial comparing the overall survival of participants with metastatic castration-resistant prostate cancer receiving xaluritamig versus cabazitaxel or second androgen receptor-directed therapy. The trial aims to enroll 675 participants and is set to be completed by November 2029. The study focuses on various outcome measures, including overall survival, radiographic progression-free survival, and objective response rate, among others. The trial is interventional, with a randomized allocation and parallel intervention model, and is being conducted by Amgen. [Extracted from the article]

Researchers at Dadasaheb Balpande College of Pharmacy in Maharashtra, India, have developed Nanostructured Lipid Carriers (NLCs) to enhance the solubility of the poorly soluble anticancer drug Flutamide. The study found that Flutamide-loaded NLCs were significantly more soluble in water and various pH solutions compared to the pure drug. This research offers a promising approach to improving the solubility of Flutamide for potential anticancer therapy. [Extracted from the article]

A recent study conducted at New York University (NYU) focused on the impact of Androgen Deprivation Therapy (ADT) on the cardiovascular system in advanced prostate cancer patients. The research highlighted the potential cardiovascular risks associated with ADT and discussed the benefits of using alternative forms of ADT, such as relugolix, which may have lower cardiovascular risks compared to other medications. The study emphasized the importance of further research to better understand and mitigate the negative cardiovascular effects of ADT in prostate cancer treatment. [Extracted from the article]

Researchers at the Carolina Urologic Research Center have conducted a study on treatment intensification for metastatic castration-resistant prostate cancer. The study focuses on combining radium-223 and enzalutamide to delay disease progression and improve overall survival. The research highlights the rationale for combining these therapies early in the disease course and discusses their differing mechanisms of action and tolerability profiles. The study draws on clinical data and emphasizes the potential benefits of this treatment approach for patients with advanced prostate cancer. [Extracted from the article]

ESSA Pharma Inc. has decided to terminate a Phase 2 clinical trial evaluating the combination of masofaniten and enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer. The decision was made based on an interim analysis showing a higher response rate with enzalutamide monotherapy and a lack of clear efficacy benefit with the combination treatment. The study, which aimed to enroll 120 patients, will not likely meet its primary endpoint, leading to the decision to end it. The company is now exploring strategic options to maximize shareholder value. [Extracted from the article]

The article discusses the development of resistance to the drug enzalutamide in prostate cancer cells. Using single-cell RNA sequencing, researchers found that a small subpopulation of cells with low or no androgen receptor expression displayed a robust transcriptional response leading to resistance to enzalutamide. Further research suggested that these cells may be vulnerable to inhibitors blocking NAD+ synthesis, providing a potential novel therapeutic option for enzalutamide-resistant prostate cancer. The study has not yet undergone peer review and more information can be found at biorxiv.org/content/10.1101/2024.10.20.619319v1. [Extracted from the article]

A recent study conducted at the St. Louis Veterans Affairs Medical Center compared the efficacy of two oral androgen-receptor targeted agents, abiraterone and enzalutamide, for metastatic castrate-resistant prostate cancer (mCRPC) in US veterans. The study found that veterans initially treated with enzalutamide had longer median overall survival compared to those treated with abiraterone, especially among patients with comorbid diseases such as cardiovascular disease or diabetes. The research suggests that further study of ARTA selection may benefit men with mCRPC and hormone-sensitive prostate cancer, particularly those with comorbidities. [Extracted from the article]

The article discusses a clinical trial, NCT06652607, focusing on metastatic castration-sensitive prostate cancer (mCSPC) and the importance of biochemical response as a prognostic factor. It highlights the significance of monitoring PSA levels to assess treatment effectiveness and patient outcomes. The study aims to evaluate patient survival based on PSA response and compare baseline characteristics between patients with or without PSA values of 0.2 ng/dl. The trial involves various drugs and therapies to assess survival outcomes based on PSA response in patients with mCSPC. [Extracted from the article]

A recent study from the University of Tehran in Iran explores the use of co-delivery systems incorporating bicalutamide (BTC) in cancer treatment, particularly in prostate cancer therapy. The research focuses on innovative delivery modalities to address challenges related to drug solubility, bioavailability, and controlled release dynamics. By combining BTC with other drugs in sustainable nanomaterials, the study aims to enhance therapeutic efficacy, potentially avoiding drug resistance mechanisms and improving patient outcomes. The findings suggest that co-delivery approaches like BTC have the potential to revolutionize cancer treatment paradigms, offering customized and optimal therapeutic options. Ongoing validation through clinical studies and meta-analyses is crucial to confirm the therapeutic value of these advancements. [Extracted from the article]

A recent study conducted at Rush University Medical Center explored the impact of concomitant medications on the treatment response and survival of patients with non-metastatic castrate-resistant prostate cancer (nmCRPC) who were receiving apalutamide therapy. The study did not find statistically significant differences in the effect of apalutamide on overall survival (OS) across subgroups stratified by exposure to commonly prescribed medication classes. However, patients treated concomitantly with metformin or ACE inhibitors (ACEI) showed significantly improved metastasis-free survival (MFS). The research concluded that exposure to concomitant metformin and ACEI was independently associated with a significant improvement in MFS. [Extracted from the article]

A patent issued by the Massachusetts Institute of Technology discusses combination therapies for treating cancer, particularly androgen-independent or castrate-resistant prostate cancer. The patent focuses on using antiandrogens or androgen antagonists in combination with polo-like kinase (Plk) inhibitors to reduce cancer cell proliferation and viability. The method aims to improve the efficacy of individual agents and treat cancers that are resistant to other therapies. The patent provides detailed information on the compositions, dosages, and methods of administration for these combination therapies. [Extracted from the article]

A recent study conducted at the University of Miami focused on metastatic hormone-sensitive prostate cancer (mHSPC) and the impact of HSD3B1 inheritance on patient outcomes. The research found that patients with low-volume mHSPC who inherited the adrenal-permissive HSD3B1 allele had better clinical progression-free survival and overall survival when treated with specific therapies. The study suggests that HSD3B1 genotype may play a role in prostate cancer mortality and could potentially be reversed pharmacologically. For more information, readers can refer to the Journal of Clinical Investigation. [Extracted from the article]

A recent study conducted at Fudan University Shanghai Cancer Center in China evaluated the efficacy and safety of enzalutamide versus placebo in Chinese men with metastatic hormone-sensitive prostate cancer. The study found that enzalutamide significantly reduced the hazard for prostate-specific antigen progression when combined with androgen deprivation therapy. Results from the China ARCHES trial were consistent with the global ARCHES study, indicating a positive impact of enzalutamide on prostate cancer treatment outcomes. For more information, the full article can be accessed for free at https://doi.org/10.1097/ju9.0000000000000198. [Extracted from the article]

The article discusses the impact of androgen receptor inhibitors on prostate cancer cells, specifically focusing on the induction of DNA replication stress by enzalutamide. The study highlights how the inhibition of translesion DNA synthesis can lead to DNA damage and vulnerability in AR-positive prostate cancer cells. The findings suggest a potential targeted therapy approach using a TLS inhibitor in combination with enzalutamide to suppress cancer growth. This research has not yet undergone peer review and provides valuable insights into potential treatment strategies for hormone-sensitive prostate cancer. [Extracted from the article]

University of Colorado researchers conducted a randomized phase II trial to study the effects of neoadjuvant fulvestrant alone or in combination with enzalutamide on ER+/HER2- breast cancer. The study aimed to assess the impact of adding androgen receptor blockade to fulvestrant on limiting residual tumor growth before surgery. Results showed that the combination therapy achieved a higher PEPI = 0 response, Ki67 response, and exhibited a more activated tumor immune microenvironment compared to fulvestrant alone. The study also found that patients with ILC had a higher odds of response compared to IDC. [Extracted from the article]

A recent study conducted at Bu Ali Sina University in Hamadan, Iran, focused on the late-stage modification of the anti-cancer drug flutamide through an electrochemical method. The research successfully synthesized new flutamide derivatives on a gram-scale without the need for catalysts or oxidants/reductants. These synthesized compounds were tested for antibacterial activity, showing promising results. The study was peer-reviewed and provides valuable insights into potential advancements in cancer treatment and drug modification. [Extracted from the article]

A recent study conducted by Johnson & Johnson has found that ERLEADA (apalutamide) provides a statistically significant overall survival benefit compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC). The study, which analyzed nearly 4,000 patients, represents the largest real-world, head-to-head analysis of these two androgen receptor pathway inhibitors (ARPIs) in mCSPC. The analysis showed that patients who initiated ERLEADA as their first ARPI had a 23% reduction in their risk of death at 24 months compared to patients who initiated on enzalutamide. These findings provide valuable real-world insights for prescribers when choosing an ARPI for patients with mCSPC. [Extracted from the article]

A recent study conducted in Karnataka, India, focused on formulating and evaluating nanostructured lipid carriers (NLCs) of the anticancer drug Flutamide. The researchers used a specific method to create the NLCs and found that they had a spherical morphology and smooth texture. The optimized Flutamide-loaded NLCs showed high encapsulation efficiency and demonstrated promising results in in vitro cell line studies on prostate cancer cells. This research suggests that NLCs could be a potential method for delivering Flutamide orally in the treatment of prostate cancer. [Extracted from the article]

A study conducted by researchers at Tongji University in Shanghai, China, has found that extrachromosomal circular DNA (eccDNA) plays a role in the development and drug resistance of prostate cancer. The researchers used Circle-seq to study the distribution and expression of eccDNA in prostate cancer and identified a gene called SPOCK1 that promotes drug resistance and metastasis through the epithelial-mesenchymal transition (EMT) mechanism. The study suggests that upregulated genes in the form of eccDNA are oncogenes in prostate cancer and play a significant role in carcinogenesis. This research provides valuable insights into potential targets for the treatment of advanced prostate cancer. [Extracted from the article]

A patent application titled "Modulation Of Androgen Signaling To Innate Immune Killing Of Prostate Cancer" discusses methods for treating prostate cancer by administering a combination of an androgen receptor inhibitor (ARi) and an agent that activates natural killer (NK) cells. The androgen pathway plays a significant role in prostate cancer initiation and progression, and blocking this pathway is crucial for treatment. However, current immunotherapy strategies for prostate cancer have limited efficacy. The inventors propose a novel approach that combines ARi and NK cell activation to enhance the immune response against prostate cancer cells. [Extracted from the article]

A study conducted by Duke University in Durham, North Carolina compared the clinical use and outcomes of three novel androgen receptor inhibitors (ARIs) - darolutamide, enzalutamide, and apalutamide - in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). The study analyzed data from electronic medical records of 870 patients and found that darolutamide had better tolerability and lower risk of treatment discontinuation and progression to metastatic CRPC compared to enzalutamide and apalutamide. The study suggests that darolutamide may have a clinical effectiveness advantage, but further comparative clinical studies are needed. The research was supported by Bayer Healthcare Pharmaceuticals. [Extracted from the article]

A patent has been issued for repurposing anti-androgen therapy for COVID-19 and immunotherapy. The patent explores the use of an Androgen Receptor (AR) antagonist, such as enzalutamide, to reduce inflammation in males and prime the lung environment for immunotherapy. The inventors have established a link between AR signaling and IL-6 expression, suggesting that enzalutamide may be useful in reducing inflammatory genes in COVID-19 patients. The patent provides a method of treating lung inflammation in COVID-19 patients by administering an AR antagonist via inhalation. [Extracted from the article]

A study conducted at Comenius University in Slovakia compared the impact of abiraterone acetate plus prednisone (abiraterone) and enzalutamide on the quality of life of patients with metastatic castration-resistant prostate cancer (mCRPC). The study included 36 patients who were treated with either abiraterone or enzalutamide according to routine practice. The researchers assessed the patients' health-related quality of life using questionnaires at baseline and at 3-, 6-, 9-, and 12-month visits. The study found that both abiraterone and enzalutamide had a comparable impact on the quality of life of patients with mCRPC. [Extracted from the article]

A study conducted by investigators from the University of Miami focused on the HSD3B1 genotype and its impact on outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) patients receiving androgen deprivation therapy (ADT) and enzalutamide. The study found that there were no significant differences in clinical efficacy endpoints between different genotypes. However, men with the adrenal-permissive (AP) genotype had higher post-progression mortality and experienced more treatment-emergent adverse events, such as hypertension, cardiovascular events, and gynecomastia. Overall, enzalutamide was found to be beneficial for men with mHSPC regardless of their HSD3B1 genotype. The study suggests that inherited polymorphisms of HSD3B1 may contribute to differential toxicities. [Extracted from the article]

A clinical trial, NCT06582628, is currently underway in Spain to evaluate the effectiveness of talazoparib plus enzalutamide as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in patients whose disease has progressed on abiraterone. The trial aims to determine if the combination of talazoparib and enzalutamide is more effective than enzalutamide alone, as well as the time to disease progression and the medical issues experienced by participants. The trial is ongoing and is expected to be completed by January 31, 2026. Another clinical trial, titled "Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)," is currently recruiting participants and is expected to be completed by October 2027. This trial will compare the combination of talazoparib and enzalutamide to enzalutamide alone to determine if the combination improves the PSA response rate and delays progression. The study will also assess the safety and tolerability of the combination treatment. The eligibility criteria for this trial include willingness to provide blood samples and consent for DNA analysis, documented evidence of metastatic prostate cancer, asymptomatic or minimally symptomatic cancer, estimated life expectancy of at least 6 months, ongoing androgen deprivation therapy, disease progression after treatment with abiraterone, and adequate organ function [Extracted from the article]

A recent report from the First People's Hospital of Hefei highlights the role of CBX2 in promoting resistance to enzalutamide, a common treatment for advanced prostate cancer. The researchers used bioinformatics analysis to identify CBX2 as a crucial factor in mediating resistance to enzalutamide by inhibiting the P53 signaling pathway. Silencing CBX2 led to increased levels of P53 expression in cancer cells, suggesting that CBX2 could be a potential therapeutic target for individuals with enzalutamide resistance. This research provides valuable insights into the development of more effective treatments for prostate cancer. [Extracted from the article]

A recent study conducted by researchers at Newcastle University Centre for Cancer in the United Kingdom has found that sialylation inhibition can partially reverse acquired resistance to enzalutamide therapy in prostate cancer cells. Enzalutamide is a commonly used treatment for castrate-resistant prostate cancer, but patients often develop secondary resistance to the drug. The study discovered that prostate cancer cells with acquired resistance to enzalutamide have increased levels of a2,6-sialylated N-glycans, and inhibiting sialylation can partially reverse this resistance. The findings suggest that combining enzalutamide therapy with sialic acid blockade may be a promising approach for treating advanced prostate cancer. [Extracted from the article]

The article focuses on a study investigating the use of stereotactic body radiotherapy (SBRT) in patients with metastatic castration-resistant prostate cancer experiencing oligoprogression during androgen receptor-targeted therapy. Topics include the retrospective analysis of patient outcomes with SBRT, the impact of SBRT on survival and treatment continuity, and the safety and efficacy of this approach in managing oligoprogressive disease.

The article focuses on evaluating the effectiveness of standard treatments for BRCA1/2 positive metastatic castration-resistant prostate cancer (mCRPC). Topics include the comparative efficacy of abiraterone, enzalutamide, and docetaxel, the impact of these treatments on PSA response and progression-free survival, and the lack of significant overall survival differences among the therapies.

The article focuses on a study comparing the effectiveness of abiraterone acetate and enzalutamide for treating metastatic castration-resistant prostate cancer (mCRPC). Topics include the comparative overall survival, prostate cancer-specific survival, and time to treatment switching or PSA response for both treatments, as well as variations in outcomes based on patient subgroups and prior treatments.

The article focuses on the U.S. Food and Drug Administration (FDA) approval of talazoparib combined with enzalutamide for treating homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). Topics discussed include the trial's significant improvements in radiographic progression-free survival (rPFS), the specific patient population targeted, and the rationale for limiting approval to HRRm mCRPC patients.

A recent study conducted by researchers at Bogazici University examined the cardiovascular risks associated with two standard hormonal therapies, abiraterone acetate (AA) and enzalutamide (ENZ), used in the treatment of prostate cancer. The study analyzed data from January 2019 to June 2023 and found no statistically significant differences in cardiovascular events between patients treated with AA and ENZ. The most common cardiovascular events observed were heart failure, atrial fibrillation, and hypotension. The study provides real-world evidence of the cardiovascular risk of these therapies, which may not be apparent in clinical trial settings. [Extracted from the article]

The article focuses on the research from the National Cancer Institute (NCI), which presents a new study on the quantitative analysis of serial positron emission tomography (PET) imaging in men with metastatic castration-resistant prostate cancer treated with enzalutamide, aiming to understand the dynamics of PET imaging in this patient population.

A recent study conducted by researchers at Guru Ghasidas Vishwavidyalaya in India explored the potential of novel analogues of the drug Apalutamide as therapeutics for prostate cancer. Prostate cancer is the second most common type of cancer in men and a leading cause of mortality worldwide. The researchers used computational methods to design and evaluate 1,415 analogues of Apalutamide, selecting 80 bioisosteres based on their pharmacokinetic profiles and drug likeness. The study found that two of the analogues, APL43 and APL80, showed promise as potential antiandrogen drugs for the treatment of prostate cancer. [Extracted from the article]

A recent study conducted at University Hospital A. Coruna in Spain examined the clinical outcomes of enzalutamide therapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The study aimed to determine whether age affected the efficacy and tolerability of enzalutamide treatment. The results showed that enzalutamide improved overall survival and reduced disease spread in both younger and older patients, although younger patients had more favorable survival outcomes. The study suggests that enzalutamide may be a useful treatment option for patients with mHSPC, regardless of age. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Zhengzhou University explored the role of reactive oxygen species (ROS) in prostate cancer. The researchers found that enzalutamide, an anti-prostate cancer drug, inhibits the function of PEX10, a protein involved in ROS regulation. This inhibition enhances the anti-tumor effect of ROS activators, potentially providing a new strategy for prostate cancer treatment. The study highlights the importance of further investigating the mechanism and potential applications of enzalutamide in the treatment of prostate cancer. [Extracted from the article]

A preprint abstract from biorxiv.org discusses a study on the combination therapy of ONC201 or ONC206, Enzalutamide, and Darolutamide in preclinical studies of castration-resistant prostate cancer. The study investigates the efficacy of these drugs in combination and their effects on tumor growth and survival. The results show that combinations of ONC201 and darolutamide or enzalutamide have synergistic effects in castration-resistant prostate cancer cells. Further translational and clinical studies are needed to explore the potential of these combinations for the treatment of advanced or metastatic prostate cancer. Please note that this preprint has not been peer-reviewed. [Extracted from the article]

Researchers at Complutense University of Madrid have conducted a study on the use of bicalutamide, a non-steroidal anti-androgen, in combination with doxorubicin and docetaxel chemotherapy for the treatment of inflammatory breast cancer (IBC) and inflammatory mammary cancer (IMC) in humans and canines. The study found that bicalutamide enhanced the effectiveness of chemotherapy in reducing cell viability, migration, and tumor growth in both cell lines. Additionally, the combination treatment increased intratumoral testosterone levels, which have been associated with reduced tumor progression. The researchers suggest that the addition of bicalutamide to chemotherapy may be a potential treatment option for IBC and IMC. [Extracted from the article]

A study conducted by researchers at Taibah University in Yanbu, Saudi Arabia, explores the potential of a new class of compounds called pyrazolylmethylene-2-thioxoimidazolidin-4-one derivatives as treatments for prostate cancer. The compounds were synthesized and tested for their anticancer effects on prostate cancer cells. The results showed promising potential for these compounds as effective treatments for prostate cancer, with some compounds demonstrating selectivity towards androgen-sensitive prostate cancer cells. Further investigation is recommended. The study was funded by the Deputyship For Research And Innovation, Ministry of Education in Saudi Arabia. [Extracted from the article]